Northern Trust Corp Gt Biopharma, Inc. Transaction History

Northern Trust Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.46 - $1.05 $285 - $651	-620 Reduced 1.88%	32,347 $17,000
Q3 2022 Nov 14, 2022	SELL	$1.81 - $56.1 $11,480 - $355,842	-6,343 Reduced 16.14%	32,967 $58,000
Q2 2022 Aug 12, 2022	SELL	$1.64 - $3.11 $204,147 - $387,132	-124,480 Reduced 76.0%	39,310 $118,000
Q1 2022 May 13, 2022	SELL	$2.6 - $3.3 $17,329 - $21,994	-6,665 Reduced 3.91%	163,790 $472,000
Q4 2021 Feb 08, 2022	BUY	$3.05 - $7.08 $10,248 - $23,788	3,360 Added 2.01%	170,455 $520,000
Q3 2021 Nov 15, 2021	SELL	$6.68 - $15.26 $389,858 - $890,604	-58,362 Reduced 25.89%	167,095 $1.13 Million
Q2 2021 Aug 13, 2021	BUY	$7.19 - $18.96 $1.37 Million - $3.62 Million	191,070 Added 555.65%	225,457 $3.5 Million
Q1 2021 May 12, 2021	BUY	$4.4 - $8.84 $151,302 - $303,981	34,387 New	34,387 $235,000

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $81.7M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.